Natera, Inc. (NTRA)
Chart Events
Performance Outlook
| Previous Close | 55.12 |
| Open | 54.27 |
| Bid | 52.86 x 800 |
| Ask | 53.06 x 900 |
| Day's Range | 52.78 - 54.75 |
| 52 Week Range | 26.10 - 129.09 |
| Volume | |
| Avg. Volume | 1,336,079 |
| Market Cap | 5.278B |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.89 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 84.91 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NTRA
Related Research
- Natera, Inc.Analyst Report: Agilent Technologies, Inc.Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.RatingFair ValueEconomic Moat14 hours agoMorningstar
- PR Newswire
Natera Announces Enrollment Completion for RenaCARE Study
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced full enrollment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, a real world, prospective, multi-center clinical study to assess the clinical utility of Natera's Renasight™ genetic testing panel, which analyzes more than 380 genes related to kidney disease. Enrollment in the study was completed early as a result of statistically meaningful interim data analysis. The study includ
- PR Newswire
Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and for 22q11.2 deletion syndrome.
- Zacks
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of -2.04% and 2.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
